SCHEMBL6775008

SCHEMBL6775008

COc1cc(C(C)(C)O)cc(Br)c1Oc1nc(C)nc(N2CCOCC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 2/20 0.47
KMT2A Q03164 5/20 0.38
HSD17B10 Q99714 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 3/20 0.38
TSHR P16473 3/20 0.38
KDM4E B2RXH2 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
MEN1 O00255 4/20 0.37
POLB P06746 2/20 0.37
MAPT P10636 2/20 0.37
MTOR P42345 2/20 0.36
PIK3CA P42336 1/20 0.36
ALOX15 P16050 2/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6780509 0.90 MEN1 (0.39) CRHR1KMT2AHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6781376 0.90 MEN1 (0.39) CRHR1KMT2AHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6770527 0.82 CRHR1 (0.45) CRHR1KMT2AHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6774484 0.82 CRHR1 (0.45) CRHR1KMT2ASMN1; SMN2ALDH1A1TSHR
SCHEMBL6770041 0.82 CRHR1 (0.46) CRHR1KMT2AHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6775364 0.78 ALOX15 (0.35) MTORPIK3CAALOX15
SCHEMBL6775265 0.76 CRHR1 (0.51) CRHR1KMT2ASMN1; SMN2MAPK1KDM4E
SCHEMBL6770815 0.73 KMT2A (0.39) CRHR1KMT2AHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6780139 0.72 TSHR (0.40) CRHR1KMT2ASMN1; SMN2ALDH1A1TSHR
SCHEMBL6770576 0.72 KMT2A (0.39) CRHR1KMT2AHSD17B10SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818648-B2 PSYCHOLOGICAL DISORDERS; ANXIOLYTIC AGENTS; ANTIDEPRESSANTS; EATING DISORDERS; ALCOHOLISM; DRUG ABUSE; ANTIINFLAMMATORY AGENTS BRISTOL-MYERS SQUIBB PHARMA 2004-11-16 US disclosed
US-20030191125-A1 Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-10-09 US disclosed
US-20020040026-A1 Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof DUPONT PHARMACEUTICALS COMPANY 2002-04-04 US disclosed
US-6326368-B1 PSYCHOLOGICAL DISORDERS DUPONT PHARMACEUTICALS COMPANY 2001-12-04 US disclosed
EP-0920318-A4 ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF DU PONT PHARM CO (US) 2000-03-15 EP disclosed
EP-0920318-A1 ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF Du Pont Pharmaceuticals Company (US) 1999-06-09 EP disclosed
WO-1997035580-A1 ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF DU PONT PHARMACEUTICALS COMPANY (US) 1997-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191125-A1 Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof PARL, HTR5A, PSEN2 CRHR1 51/4885KMT2A 3678/4885HSD17B10 3028/4885
US-20020040026-A1 Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof PARL, HTR5A, PSEN2 CRHR1 53/4885KMT2A 3659/4885HSD17B10 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.